(Q44115416)

29 November 2017

title

Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer (English)

1 reference

29 November 2017

main subject

phase I clinical trial

0 references

1 reference

Timothy M Kuzel

1 reference

29 November 2017

Merrill S Kies

1 reference

29 November 2017

Nini Wu

1 reference

29 November 2017

Yi-Ching Hsieh

1 reference

29 November 2017

Alfred W Rademaker

1 reference

29 November 2017

publication date

1 January 2002

1 reference

29 November 2017

1 reference

29 November 2017

1 reference

29 November 2017

issue

5-6

1 reference

29 November 2017

page(s)

634-643

1 reference

29 November 2017

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Estramustine Phosphate Sodium

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Taxol in advanced, hormone-refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Phase I and pharmacologic study of estramustine phosphate and short infusions of paclitaxel in women with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Weekly 1-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120002488

21 January 2018

Identifiers

DOI

10.1081/CNV-120002488

1 reference

29 November 2017

1 reference